| Oct 08 | Oct 07 | Oct 06 | Oct 05 | Oct 04 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | |||||
| Gross Profit | $ 8.97M | $ 6.63M | $ 2.36M | $ -37.10K | $ 80.50K |
| Operating Income | $ -2.48M | $ -10.26M | $ -3.62M | $ -1.91M | $ -786.41K |
| EBITDA | $ -1.87M | $ -9.93M | $ -2.27M | $ -1.84M | $ -755.53K |
| Net Income | $ -4.01M | $ -20.86M | $ -8.57M | $ -2.91M | $ -1.12M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ ― | $ ― | $ ― | $ ― | $ ― |
| Total Assets | $ 22.35M | $ 23.33M | $ 38.88M | $ 16.91M | $ 2.88M |
| Total Debt | $ 6.55M | $ 18.75M | $ 17.87M | $ 4.30M | $ 0.00 |
| Net Debt | $ 6.49M | $ 18.75M | $ 15.47M | $ 4.17M | $ -629.26K |
| Total Liabilities | $ 17.34M | $ 31.44M | $ 25.78M | $ 5.61M | $ 1.97M |
| Stockholders' Equity | $ ― | $ ― | $ ― | $ ― | $ ― |
| Cash Flow | |||||
| Free Cash Flow | $ 3.15M | $ -4.39M | $ -6.76M | $ -2.50M | $ -653.90K |
| Operating Cash Flow | $ 3.86M | $ -3.68M | $ -5.17M | $ -2.26M | $ -640.40K |
| Investing Cash Flow | |||||
| Financing Cash Flow |
Synovics Pharmaceuticals Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.